Impact of COVID-19
important-icon

The information below is intended solely to help educate healthcare providers about COVID-19.
It is not a statement of vaccine efficacy or effectiveness.

It is important to keep eligible individuals up to date with COVID-19 vaccination to help protect against COVID-19 and potential severe outcomes1

COVID-19 continues to cause severe outcomes, including hospitalization and death in some people2,5

Note: The United States Centers for Disease Control and Prevention (CDC) defines severe outcomes of COVID-19 as hospitalization, admission to the intensive care unit (ICU), intubation or mechanical ventilation, or death.4

img Actor portrayals.

COVID-19–associated deaths
from October 1, 2023, to March 29, 20256

According to provisional data
from the National Vital Statistics
System, there were:

~78,000

COVID-19–associated deaths across all age groups in the US6†

†The National Center for Health Statistics uses data from death certificates to produce provisional COVID-19 death counts for the 50 states and Washington, DC, based on ICD-10 code U07.1 (including confirmed and probable cases). Provisional counts may differ from other sources and typically lag 1 to 2 weeks behind due to the time required to complete death certificates and delays in testing or state reporting. Provisional data may be incomplete and subject to revision, and should not be compared across states due to differing reporting practices.6 For more detailed technical information about provisional death counts, please visit
https://
www.cdc.gov/nchs/nvss/vsrr/covid19/tech_notes.htm

COVID-19–associated hospitalizations continue to be a year-round risk2,7

RESP-NET rates of weekly COVID-19–associated or
flu-associated hospitalizations in the US

Laboratory-confirmed hospitalizations associated with COVID-19 or influenza in adults from October 1, 2023, to September 28, 2024
(per 100,000 people)2,7

Laboratory-confirmed hospitalizations associated with COVID-19 or influenza in adults from October 1, 2024, to February 1, 2025
(per 100,000 people)2,7

graph

Notes

  • RESP-NET also reports other pathogens not represented here2,7
  • Source: Respiratory Virus Hospitalization Surveillance Network (RESP-NET)7
  • Additional information available at: https://www.cdc.gov/resp-net/dashboard/index.html
  • Data are collected for all ages through a network of acute care hospitals in select counties or county equivalents in 13 states for COVID-19 surveillance and 14 states for influenza surveillance. COVID-NET covers more than 34 million people and includes an estimated 10% of the US population. The COVID-19 surveillance area is generally similar to the US population by demographics, however, COVID-NET data might not
    be generalizable to the entire country2,7
  • Data are preliminary and subject to change as more data become available. In particular, case counts and rates for recent hospital admissions are subject to lag. Data may be affected by potential reporting delays; caution should be taken when interpreting these data2,7
  • Incidence rates of respiratory virus-associated hospitalizations (per 100,000) are calculated using the US Census vintage 2023 unbridged-race postcensal population estimates for the counties or county equivalents included in the surveillance area2,7
  • These rates are likely to be underestimated as some RESP-NET–associated hospitalizations might be missed because of undertesting, differing provider or facility testing practices, and diagnostic test sensitivity. Rates presented do not adjust for testing practices, which may differ by pathogen, age, race and ethnicity, and other demographic criteria2,7
  • Surveillance for COVID-19– and influenza-associated hospitalizations is typically conducted between October 1 and April 30, but recent years have seen COVID-NET and FluSurv-NET conduct surveillance past April 30 due to observed pathogen-specific trends in activity. As per RESP-NET, the surveillance season for COVID-19 extended through September 30, 2024, while the influenza surveillance season is extended to "present." The data shown in the graph reflect information through September 28, 20242,7

Notes

  • RESP-NET also reports other pathogens not represented here2,7
  • Source: Respiratory Virus Hospitalization Surveillance Network (RESP-NET)7
  • Additional information available at: https://www.cdc.gov/resp-net/dashboard/index.html
  • Data are collected for all ages through a network of acute care hospitals in select counties or county equivalents in 13 states for COVID-19 surveillance and 14 states for influenza surveillance. COVID-NET covers more than 34 million people and includes an estimated 10% of the US population. The COVID-19 surveillance area is generally similar to the US population by demographics, however, COVID-NET data might not
    be generalizable to the entire country2,7
  • Data are preliminary and subject to change as more data become available. In particular, case counts and rates for recent hospital admissions are subject to lag. Data may be affected by potential reporting delays; caution should be taken when interpreting these data2,7
  • Incidence rates of respiratory virus-associated hospitalizations (per 100,000) are calculated using the US Census vintage 2023 unbridged-race postcensal population estimates for the counties or county equivalents included in the surveillance area2,7
  • These rates are likely to be underestimated as some RESP-NET–associated hospitalizations might be missed because of undertesting, differing provider or facility testing practices, and diagnostic test sensitivity. Rates presented do not adjust for testing practices, which may differ by pathogen, age, race and ethnicity, and other demographic criteria2,7
  • Surveillance for COVID-19– and influenza-associated hospitalizations is typically conducted between October 1 and April 30, but recent years have seen COVID-NET and FluSurv-NET conduct surveillance past April 30 due to observed pathogen-specific trends in activity. As per RESP-NET, the surveillance season for COVID-19 extended through September 30, 2024, while the influenza surveillance season is extended to "present." The data shown in the graph reflect information through February 1, 20252,7

CDC recommendations for COVID-19 vaccination include eligible adults,
but the vaccination rate remains low1,8

Estimated vaccination rates for 2024-2025 formula COVID-19 vaccine and influenza vaccine

September 2024 to February 20258  |  In adults 18 years of age and older8:

COVID-19

COVID-19

Influenza

Influenza

COVID-19 Vaccination Rate

blue-20

Influenza Vaccination Rate

green-39
Source: National Immunization Survey-Adult COVID Module (NIS-ACM). These data are weekly estimates of COVID-19 vaccination coverage and intent for vaccination among adults and are calculated from the NIS-ACM.8
Despite high rates of infection in the fall and winter months,
these two potentially serious respiratory illnesses have low vaccination rates1,8,9

COVID-19 vaccination coverage estimates presented represent uptake or intent for uptake of the 2024-2025 COVID-19 vaccine. Vaccination coverage estimates are based on all interviews through the current week and represent approximately the cumulative percent vaccinated by mid-week. Each week, estimates for prior weeks are recalculated using the additional interviews conducted that week, combined with all previous interviews. Estimates for vaccination intent are based on interviews conducted that week and are adjusted to the cumulative vaccination coverage estimate for that week.8

The NIS-ACM adult flu vaccination coverage estimates for prior season(s) are based on interviews conducted during each analysis period and can increase or decrease over time due to random sampling variation.8

Message

According to the CDC, routine simultaneous administration‡ of all age-appropriate vaccines is recommended if there are no contraindications at the time of the visit.10§

‡Special considerations apply to coadministration of orthopoxvirus vaccines. Refer to CDC clinical guidance for information.10

§Simultaneous administration is defined as administering more than 1 vaccine on the same clinic day, at different anatomic sites, and not combined in the same syringe.11

Select Underlying Medical Conditions and Risk Factors

Individuals with certain underlying medical conditions or risk factors may be at increased risk of severe outcomes*
from COVID-191,10

Medical conditions or risk
factors that can increase risk
of severe outcomes from COVID-19 include4†:

person1Aged 65 years and older

asthma_wheeingAsthma

kidney1Chronic kidney disease

abdo1Chronic liver disease

copd1COPD

cancer1Cancer

diebate1Diabetes mellitus (type 1 or type 2)

heart1Heart conditions

obesity2Obesity

obesity2Smoking

*The United States Centers for Disease Control and Prevention (CDC) defines severe outcomes of COVID-19 as hospitalization, admission to the intensive care unit (ICU), intubation or mechanical ventilation, or death.4

†List is not in alphabetical order and is not a complete list or in order of risk.

To see a complete list of the factors that increase the risk of severe illness from COVID-19, click here.

exclamicon

By clicking this link, you will be redirected to a website that is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of this site.

COVID-19–associated hospitalizations in individuals with 1 or more underlying medical conditions2

October 1, 2023, to September 30, 20242‡

According to COVID-NET,‡ of all COVID-19–associated
hospitalizations in the US:

~66%

were in adults 18 to 49 years of age2

91%-96%

were in adults 50
years of age and older2

‡According to COVID-NET, a case is defined as laboratory-confirmed SARS-CoV-2 in a person residing in a COVID-NET surveillance area who tests positive within 14 days before or during hospitalization. COVID-NET covers 185 counties and county equivalents in 13 states nationwide. It includes an estimated 10% of the US population and is generally similar to the US population by demographics, though data might not be generalizable to the entire country. The COVID-NET surveillance season begins on Week 40 of the calendar year (on or around October 1) and continues through Week 39 of the following calendar year (on or around September 30). Surveillance for the 2023-2024 season began on October 1, 2023; additional data points are added as data are available.2 Additional information available at: https://www.cdc.gov/covid/php/covid-net/index.html

Age is the strongest risk factor for severe outcomes§ from COVID-194||

Observed risk of severe outcomes increases substantially in people 65 years of age and older4

In hospitalization surveillance conducted
from October 1, 2023, to September 30, 2024,
according to COVID-NET, among all patients admitted to the
hospital due to COVID-19,
it is estimated that2||:

hospital1

63%-71%

were adults aged 65 years
and older2

§The United States Centers for Disease Control and Prevention (CDC) defines severe outcomes of COVID-19 as hospitalization, admission to the intensive care unit (ICU), intubation or mechanical ventilation, or death.4

∥According to COVID-NET, a case is defined as laboratory-confirmed SARS-CoV-2 in a person residing in a COVID-NET surveillance area who tests positive within 14 days before or during hospitalization. COVID-NET covers 185 counties and county equivalents in 13 states nationwide. It includes an estimated 10% of the US population and is generally similar to the US population by demographics, though data might not be generalizable to the entire country. The COVID-NET surveillance season begins on Week 40 of the calendar year (on or around October 1) and continues through Week 39 of the following calendar year (on or around September 30). Surveillance for the 2023-2024 season began on October 1, 2023; additional data points are added as data are available.2 Additional information available at: https://www.cdc.gov/covid/php/covid-net/index.html

Please refer to https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covid-net/purpose-methods.html for the most current information related to CDC data collection.

exclamicon

By clicking this link, you will be redirected to a website that is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of this site.

Provider Support

Speaking with eligible individuals
about COVID-19 vaccination can be
an important first step in helping to
build vaccine confidence12

Actor portrayals.

A healthcare professional’s recommendation is one of
the strongest predictors of whether an eligible
individual gets vaccinated12

bandage

According to the CDC, routine simultaneous administration* of all age-appropriate vaccines is recommended if there
are no contraindications at the time of the visit.10†

*Special considerations apply to coadministration of orthopoxvirus vaccines. Refer to CDC clinical guidance for information.10

†Simultaneous administration is defined as administering more than 1 vaccine on the same clinic day, at different anatomic sites, and not combined in the same syringe.11

CDC Resource

The CDC recommends healthcare providers talk to
patients about what vaccines they may need.
Here is a CDC resource that might help the conversation:

exclamicon

By clicking this link, you will
be redirected to a website that is neither owned nor controlled by Pfizer. Pfizer is not responsible for the content or services of this site.

CDC=Centers for Disease Control and Prevention; COPD=chronic obstructive pulmonary disease; COVID-NET=Coronavirus Disease 2019 (COVID-19) Hospitalization Surveillance Network;
FluSurv-NET=Influenza Hospitalization Surveillance Network; ICD=International Classification of Diseases; RESP-NET=Respiratory Virus Hospitalization Surveillance Network; SARS-
CoV-2=severe acute respiratory syndrome coronavirus 2.

Ordering available through Pfizer Prime*

Orders for 2024-2025 formula COVID-19 vaccines by BioNTech and Pfizer can be placed by eligible
healthcare professionals directly with Pfizer through Pfizer Prime online or by calling 1-800-533-4535.

Visit Pfizer Prime

*Eligible healthcare providers can order COVID-19 vaccines directly from
Pfizer. If preferred, orders may be placed with your facility’s wholesaler.

IMPORTANT SAFETY INFORMATION

Do not administer COMIRNATY® (COVID-19 Vaccine, mRNA) to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of COMIRNATY or to individuals who had a severe allergic reaction (e.g., anaphylaxis) following a previous dose of a Pfizer-BioNTech COVID-19 vaccine.

Management of Acute Allergic Reactions

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of COMIRNATY.

Myocarditis and Pericarditis

Postmarketing data from use of authorized or approved mRNA COVID-19 vaccines, including COMIRNATY, have demonstrated increased risks of myocarditis and pericarditis, with onset of symptoms typically in the first week following vaccination. The observed risk has been highest in males 12 years through 24 years of age.

Syncope

Syncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY. Procedures should be in place to avoid injury from fainting.

Altered Immunocompetence

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to COMIRNATY.

Limitation of Vaccine Effectiveness

COMIRNATY may not protect all vaccine recipients.

Adverse Reactions

The most commonly reported adverse reactions (≥10%) after a dose of COMIRNATY were pain at the injection site (up to 90.5%), fatigue (up to 77.5%), headache (up to 75.5%), chills (up to 49.2%), muscle pain (up to 45.5%), joint pain (up to 27.5%), fever (up to 24.3%), injection site swelling (up to 11.8%), and injection site redness (up to 10.4%).

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at
1-800-438-1985 or https://www.pfizersafetyreporting.com or VAERS at
1-800-822-7967 or https://vaers.hhs.gov

Please click for COMIRNATY Full Prescribing Information and Patient Information.

PP-CVV-USA-5217

INDICATION

COMIRNATY® (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.

Please click for COMIRNATY Full Prescribing Information and Patient Information.

PP-CVV-USA-5217

Expand

For more information

Headset Icon
Pfizer Customer
Service

Including General Product Questions.

Call 1-800-879-3477
Information Icon Medical
Information
Visit PfizerMedicalInformation.com
Globe Icon Shipment Support
US Trade Customer Service
Call 1-800-666-7248
Headset Icon

Pfizer Customer Service

Including General
Product Questions.

Call 1-800-879-3477

Information Icon

Medical Information

Visit
PfizerMedicalInformation.com

Globe Icon

Shipment Support US Trade Customer Service

Call 1-800-666-7248

Text Updates Icon Get COVID-19 Vaccine
Text Updates Enroll in the BioNTech & Pfizer COVID Connect text messaging program for U.S. Healthcare Professionals.
Phone Icon Call a Pfizer Connect
Representative Live representatives are available 9 AM–5 PM ET to help HCPs answer product questions, discuss Pfizer Prime ordering, and more.
Call 1-844-966-5127
References: References: References
  1. Staying up to date with COVID-19 vaccines. Centers for Disease Control and Prevention. Updated June 6, 2025. Accessed June 18, 2025. https://www.cdc.gov/covid/vaccines/stay-up-to-date.html
  2. COVID-NET interactive dashboard. Centers for Disease Control and Prevention. Accessed June 17, 2025. https://www.cdc.gov/covid/php/covid-net/index.html
  3. Long COVID basics. Centers for Disease Control and Prevention. Updated July 11, 2024. Accessed December 12, 2024. https://www.cdc.gov/covid/
    long-term-effects/index.html
  4. Underlying conditions and the higher risk for severe COVID-19. Centers for Disease Control and Prevention. Updated February 6, 2025. Accessed February 11, 2025. https://www.cdc.gov/covid/hcp/clinical-care/underlying-conditions.html
  5. Provisional mortality statistics, 2018 through last week results. Deaths occurring through February 15, 2025 as of February 23, 2025. WONDER online database. Centers for Disease Control and Prevention. Updated February 23, 2025. Accessed March 3, 2025. https://wonder.cdc.gov/mcd-icd10-provisional.html
  6. Provisional COVID-19 mortality surveillance. Centers for Disease Control and Prevention. Updated June 12, 2025. Accessed June 17, 2025. https://www.cdc.gov/nchs/nvss/vsrr/covid19/index.htm
  7. Respiratory virus hospitalization surveillance network (RESP-NET). Centers for Disease Control and Prevention. Updated June 5, 2025. Accessed June 17, 2025. https://www.cdc.gov/resp-net/dashboard/index.html
  8. Vaccination trends. Centers for Disease Control and Prevention. Updated February 21, 2025. Accessed June 17, 2025. https://www.cdc.gov/respiratory-viruses/data/vaccination-trends.html
  9. Getting your immunizations for the 2024-2025 fall and winter virus season. Centers for Disease Control and Prevention. Updated September 27, 2024. Accessed June 17, 2025. https://www.cdc.gov/ncird/whats-new/getting-your-immunizations-for-the-2024-2025-fall-and-winter-virus-season.html
  10. Interim clinical considerations for use of COVID-19 vaccines in the United States. Centers for Disease Control and Prevention. Updated May 1, 2025. Accessed June 17, 2025. https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html
  11. Timing and spacing of immunobiologics. Centers for Disease Control and Prevention. Updated July 24, 2024. Accessed June 17, 2025. https://www.cdc.gov/vaccines/hcp/imz-best-practices/timing-spacing-immunobiologics.html
  12. Adult immunization standards. Centers for Disease Control and Prevention. Updated August 9, 2024. Accessed Accessed June 17, 2025. https://www.cdc.gov/vaccines-adults/hcp/imz-standards/index.html